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Abstract
Aims/hypothesis HbA1c, expressed as the percentage of
adult haemoglobin that is glycated, is the most widely used
measure of chronic glycaemia. Achieving near-normal
HbA1c levels has been shown to reduce long-term compli-
cations and the HbA1c assay is recommended to determine
whether treatment is adequate and to guide adjustments.
However, daily adjustments of therapy are guided by
capillary glucose levels (mmol/l). We determined the
relationship between an accurate measure of mean glucose
levels over time and the HbA1c level, and whether HbA1c can
be expressed in the same units as self-monitoring results.
Methods Twenty-two participants with diabetes and three
non-diabetic participants were included in this longitudinal
observational study. Mean glucose levels were measured by
continuous glucose monitoring (CGM), which measures
interstitial glucose levels every 5 min, for 12 weeks.
Capillary measurements were obtained four times per day
to confirm the accuracy of CGM. HbA1c was measured at
baseline and every 4 weeks.
Results The HbA1c results at weeks 8 and 12 correlated
strongly (r=0.90) with the CGM results during the preceding
8 and 12 weeks. A curvilinear (exponential) relationship and
a linear regression captured the relationship with similarly
high correlations, which allowed transformation of HbA1c
values to a calculated mean glucose level.
Conclusions and interpretation HbA1c correlates closely
with a complete measure of average glycaemia over the
preceding 8–12 weeks. The translation of HbA1c to an
average glucose level for reporting and management
purposes is feasible.
Keywords Diabetes . Diabetes management .
Chronic glycaemia . Glycated haemoglobin
Abbreviations
CGM continuous glucose monitoring
CGMS Continuous Glucose Monitoring System
MBG mean blood glucose concentration
NGSP National Glycohemoglobin Standardization Program
Introduction
The HbA1c assay has become the most commonly used
measure of chronic glycaemia in epidemiological studies,
clinical trials and the management of diabetes since its
introduction more than 25 years ago [1–3]. The concentra-
tion of HbA1c, formed through the non-enzymatic attach-
ment of glucose to haemoglobin, is commonly considered to
reflect the integrated mean glucose level over the previous
8–12 weeks, the time period being dictated by the 120 day
lifespan of the erythrocyte. The relationship between mean
blood glucose and HbA1c has been suggested by old studies
that used a variety of measures of outpatient and inpatient
plasma and capillary glucose concentrations, all of which
suffered from relatively infrequent sampling of glucose
levels, infrequent sampling of HbA1c, or both [4–8].
Arguably, the two most convincing studies measured four
to six fingerstick blood glucose levels per day for 6–8 weeks
and compared the calculated mean blood glucose levels with
the HbA1c levels measured at the end of the study period
[9, 10]. The clinical role of the assay was subsequently
established by demonstrating that it provided information
regarding mean blood glucose that could not be provided by
any other available measures [10]. The pre-eminent role of
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the assay was cemented by the Diabetes Control and
Complications Trial (DCCT), and others, which used the
assay to measure chronic glycaemia and demonstrated its
central role in the pathogenesis of long-term complications
[11–13]. The recommended goals for metabolic control of
diabetes are based on the HbA1c assay [2, 14, 15], the vast
majority of methods now being standardised to the DCCT
assay through an international programme [16].
Despite the popularity and central role of the HbA1c
assay, its true relationship to mean blood glucose remains
poorly understood. HbA1c appears to reach a new steady
state 3–4 months after glucose changes [17]. All of the
previous studies that suggested a relationship between
HbA1c level and mean blood glucose [4–10] used relatively
infrequent monitoring during the daytime, which is prone to
sampling error, and did not capture glucose levels overnight
or true 24 h glycaemia. In addition, the limited time period
of the previous studies and limited number of HbA1c assays
performed precluded an analysis of the time period of mean
glycaemia that the HbA1c reflects best.
We used continuous glucose monitoring (CGM), which
measures interstitial glucose levels every 5 min, for 3 months
in patients with diabetes with relatively stable glycaemia,
and in non-diabetic individuals, to determine true mean
glycaemia. HbA1c assays were measured monthly and best-
fit correlations were determined over time.
Methods
Participants Patients with type 1 (n=15) or type 2 (n=7)
diabetes mellitus were recruited from the Massachusetts
General Hospital Diabetes Center. Three non-diabetic
volunteers were also recruited. The diabetic participants
were required to have relatively stable glycaemic control,
manifest by at least two HbA1c assay results in the previous
6 months that were no more than 1% different. We tried to
recruit approximately similar numbers of diabetic partic-
ipants with HbA1c <7, 7–8.5 and >8.5%. The non-diabetic
participants had no history of diabetes and had HbA1c
levels in the non-diabetic range (<6.1%) in the assays used
for the study. Exclusion criteria included any condition that
would probably cause a change in glucose control during
the 3 month period of study or that would change
erythrocyte turnover. Potential participants with known
haemoglobinopathies were excluded to avoid any possible
interference with the HbA1c assays [18]. All participants
signed an informed consent form approved by the Human
Research Committee.
Measurements CGM was performed with the Continuous
Glucose Monitoring System (CGMS Medtronic Minimed,
Northridge, CA, USA), which measures interstitial glucose
levels every 5 min through a catheter inserted subcutane-
ously. Participants changed the sensor units every 3 days, as
instructed by the manufacturer, and returned the monitors to
the Diabetes Center every 2 weeks so that they could be
downloaded. Diabetes therapy was not adjusted on the basis
of the CGM data, unless otherwise unrecognised periods of
hypoglycaemia, such as periods of nocturnal glucose levels
<3.33 mmol/l, were noted. When this occurred, the patient’s
physician was notified so that appropriate treatment changes
could be made. In addition to the CGM, participants were
requested to perform self-monitoring of capillary glucose
(OneTouch Ultra; Lifescan, Milipitas, CA, USA) at least four
times per day, usually before meals and at bedtime. These
measurements were used to calibrate the CGMS and adjust
therapy, and provided an independent measure of glycaemia.
Capillary glucose levels are calibrated by Lifescan to provide
values equivalent to plasma glucose levels. Glucose levels
were also measured with a laboratory-based hexokinase
assay (Hitachi Model 917 autoanalyser; Hitachi, Tokyo,
Japan) at each 2 week visit to the Diabetes Center,
contemporaneously with a self-glucose monitoring test.
The capillary glucose values correlated closely with the
simultaneously measured laboratory values (n=146 pairs,
capillary value=0.8876×laboratory value+21.4, R2=
0.9629, p<0.001), validating the accuracy of the self-
monitoring. The mean absolute difference between the self-
monitored and laboratory results was <0.11 mmol/l.
Two different assays were used to measure HbA1c: an
HPLC method that is the primary reference method for the
National Glycohemoglobin Standardization Program
(NGSP) [15] and a boronate affinity assay (Primus PDQ,
Primus Diagnostics, Kansas City, MO, USA) that measures
HbA1c independently of any haemoglobin abnormalities.
Because of technical issues (modestly elevated fetal
haemoglobin levels in five participants and missing samples
at several time points for two participants), several
participants’ samples could not be assayed accurately with
the NGSP reference assay [18]. Therefore, the primary
results presented here are from the boronate affinity assay.
Both HbA1c assays have CVs <2% at low (5%) and high
(10%) HbA1c values in our laboratory. Long-term calibra-
tion standards are used to prevent assay drift in the NGSP
HPLC method and the boronate affinity assay is calibrated
against it. The correlation of the boronate affinity assay
with the primary HPLC assay is r=0.99 (p<0.001).
Statistical analyses The demographic data are expressed as
mean ± SD. Correlations between mean glucose levels
derived from the CGM results and HbA1c levels were
analysed using linear regression, exponential and quadratic
equations, with Spearman correlations. The best fits, judged
by the r values closest to 1.0, were determined. Analyses
were performed using Stata statistical software (Stata
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Statistical Software Release 8.0, 2003; Stata Corporation,
College Station, TX, USA).
Results
Twenty-nine eligible volunteers were recruited to the study.
Three volunteers withdrew within the first few weeks
because of their inability to carry out various elements of
the study. A fourth volunteer was hospitalised for medical
reasons unrelated to the study and could not complete the
study in a timely fashion. Baseline characteristics of the 25
participants who completed the 12 week study are shown in
Table 1.
The participants had HbA1c measured four times, at
baseline and monthly for 3 months. HbA1c levels during the
study changed minimally from baseline (7.39±1.4%) to
study end (7.16±1.3%), with the greatest absolute differ-
ence <1%. CGM was performed on average for 81.8±4
days of the 12-week period for the diabetic participants,
representing 97% of the possible 84 day period and
approximately 24,000 glucose measurements per partici-
pant. Self-monitoring by capillary fingerstick was per-
formed an average of 3.73±1.93 times per day by the
diabetic participants and 2.68±1.08 times per day by the
non-diabetic participants. Almost 6000 paired (simulta-
neous capillary and interstitial CGMS tests) assays were
performed.
The correlations between mean CGM glucose levels and
HbA1c levels at the different time points during the study
are shown in Table 2. The strongest correlations (Spearman
r=0.89–90, p<0.001) were between the mean CGM
glucose levels measured during the entire 12-week period
and the HbA1c level at weeks 8 or 12.
The linear and exponential models provided similarly
close correlations between the CGM during the 12 weeks of
the study and the HbA1c value at 12 weeks: linear model,
mean CGM concentration (mean CGM)=HbA1c×1.75–
3.81 (r=0.89, p<0.001) (Fig. 1a); exponential model, mean
CGM=1.28HbA1c+0.000136exp(HbA1c)–0.92 (r=0.89, p
<0.001) (Fig. 1b). The correlations of mean CGM levels
with the HbA1c values assayed with the NGSP reference
HPLC method had an r value for the linear regression of
0.90 (p<0.001).
The HbA1c values were transformed into their equivalent
mean CGM values using the exponential and linear
regression equations (Table 3). Similar transformations
with the HPLC assay results provided similar mean glucose
values (not shown).
Discussion
The HbA1c assay is widely accepted as the best means of
retrospectively capturing mean glycaemia. It is the basis of
treatment guidelines and is used universally to adjust
therapy [2, 14, 15]. In order for patients to achieve HbA1c
goals, they adjust their day-to-day therapies based on
fingerstick capillary glucose levels, measured with meters
that are adjusted to provide values comparable to venous
plasma levels [3]. However, the relationship between
HbA1c values and mean glucose levels has never been
carefully explored, owing in great part to the absence of
means to measure glucose levels frequently enough to
reveal a complete description of mean glucose levels over
time. Previous studies that have been performed have used
relatively infrequent glucose testing and have not been able
to measure mean blood glucose levels with confidence
because of potential sampling errors [4–10]. For example,
the DCCT data set included a seven-point glucose profile
performed every 3 months [8]. The intra-individual varia-
tions in mean glucose profiles and HbA1c were 29.9 and
9.7% respectively, suggesting the relatively high degree of
variability of glucose profiles collected intermittently, and
reinforcing the need for frequent measurements to capture
mean glycaemia.
We took advantage of the development of CGM devices,
which measure interstitial glucose levels every 3–5 min. By
using these devices over a 3 month period, we provided a
more complete measure, including approximately 24,000
glucose tests per participant, of the average glucose levels








n 15 7 3 25
Age (years) 49±10.1 64±9.8 43±18.8 52±13.2
Sex (% women) 53 57 67 56
Diabetes duration
(years)
28.3±11.6 21.4±8.7 N/A 26±11.0
Race (% white) 87 86 100 93
HbA1c (%) 7.6±1.0 8.1±1.4 4.9±0.3 7.4±1.4
Data are mean±SD
Table 2 Correlation of HbA1c with mean continuous glucose level
HbA1c level at
Week 4 Week 8 Week 12
Mean CGM at:
Weeks 1–4 0.83 0.81 0.79
Weeks 5–8 0.81 0.88 0.87
Weeks 9–12 0.81 0.88 0.90
Weeks 1–8 0.86 0.89 0.87
Weeks 1–12 0.86 0.90 0.89
Data are Spearman correlation coefficients; all p<0.001
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in 25 diabetic and non-diabetic individuals and determined
their relationship with HbA1c. Although some studies have
suggested less than acceptable correlations between CGMS
interstitial glucose results and venous plasma or capillary
glucose levels, most recent studies, including the present
study, have noted generally strong correlations [19, 20].
The results showed that HbA1c is tightly correlated with
mean interstitial glucose levels, with exponential and linear
regression equations providing similarly tight fits for the
data. Previous studies with less detailed measures of
chronic glucose values, including one using intermittent
CGM, have also suggested a curvilinear relationship with
HbA1c [9, 21]. The limited number of HbA1c assay results
in the higher range limits our ability to choose between the
linear and exponential models. Although the choice of
research participants with stable HbA1c levels and the
decision not to adjust therapy during the study limited our
ability to examine the dynamics of glucose change and
HbA1c levels, the strongest correlations between HbA1c and
mean glucose levels appeared to be over the preceding 12
weeks, consistent with prior studies [17].
Of note, although there was less than a perfect
correlation between the measured mean glucose levels and
the HbA1c levels, the relatively high r values, especially
given the limited sample size and range of values, suggests
that there are probably no extraneous factors that affect the
relationship between MBG and HbA1c in a substantive way.
Some studies have suggested that variable red cell turnover,
which may be affected by hyperglycaemia, may alter the
relationship between mean blood glucose and HbA1c values
[22]. Other studies have proposed that glycation rates may
differ among individuals at the same mean glucose levels
[23, 24]. However, the studies that have supported
differential rates of glycation (high vs low glycators) have
generally been performed in non-diabetic individuals with
very limited glucose testing. A study by Hempe and
colleagues in 128 children with type 1 diabetes suggested
that differential glycation occurred since mean blood
glucose levels during a 1 month period, assessed with
approximately 80 self-monitored values, did not correlate
tightly with the HbA1c at the end of the month (r=0.71)
[25]. However, the present study and others [17] strongly
suggest that a 1-month period is inadequate for HbA1c to
equilibrate and that if more complete glucose monitoring is
performed (8000 assays in 1 month in our study compared
with 80 in the Hempe study) the correlations become
substantially tighter. The absence of any major outliers in
the present study suggest that if differential glycation exists
it is relatively rare, or does not affect the relationship
between blood glucose values and HbA1c levels enough to
disturb a predictable relationship between the two. Howev-
er, considering the small sample size in the present study
and the relatively homogeneous study population, most of
the participants being white and with type 1 diabetes, larger
studies using comparable assessment of chronic glycaemia
will need to be performed to determine conclusively
whether differential glycation exists.
Fig. 1 Relationship between HbA1c at month 3 and mean glucose
level calculated from CGM during 12 previous weeks according to (a)
linear regression mean CGM=HbA1c×1.75–3.81 (r=0.89, p<0.001),
and (b) the exponential mean CGM=1.28HbA1c+0.000136exp
(HbA1c)–0.92 (r=0.89, p<0.001). Continuous line, fitted values;
diamonds, observed values
Table 3 Mean glucose equivalent values for HbA1c















a Based on linear regression mean CGM=HbA1c×1.75–3.81 (r=0.89,
p<0.001)
b Based on exponential mean CGM=1.28HbA1c+0.000136exp(HbA1c)–
0.92 (r=0.89, p<0.001)
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The relatively small number of participants precludes
any expansive conclusions regarding the relationship
between HbA1c and mean glucose levels in the larger
diabetic population. Similarly, the limited range of HbA1c
levels in the present study (the highest HbA1c level was
<11%) does not allow extrapolation of our results to
patients with HbA1c levels that are very high. However,
we are confident of our findings in the range of glycaemia
studied, and have therefore restricted the conversion table
(Table 3) to the values included in the study. While
inclusion of patients with higher HbA1c levels will be
required to determine the conversion equations covering a
wider range of glycaemia, and whether an exponential
model fits better than a linear one, the range of HbA1c
levels in the present study applies to the vast majority of
diabetic patients. Of note, similar correlations between
average chronic glycaemia and HbA1c were obtained with
all of the HbA1c assays performed; thus, the relationship is
not limited to only one HbA1c assay.
The mathematical relationship established between
HbA1c and mean blood glucose in this study should allow
the expression of HbA1c as an equivalent mean glucose
level. This is likely to be beneficial to patients and care
providers alike as the assay of chronic glucose control
would be in the same units as the patients’ self-monitoring.
However, before this transformation can take place, the
mathematical relationship between HbA1c and mean glu-
cose levels should be confirmed in a larger study with a
more diverse population to ensure that the relationship
applies for all patients with diabetes. An international study
that is examining the relationship between mean glucose
levels and HbA1c levels in a large (n=700), multinational
study population including non-diabetic participants and
type 1 and type 2 diabetic participants is ongoing. Like the
present study, the international study is employing CGMS
and frequent self-monitored capillary profiles to capture
average glucose levels as completely as possible.
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